Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis

References

• WHO. Global report on psoriasis 2016. Geneva (Switzerland): WHO Press; 2016.
   Google Scholar
• Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–516.
   PubMed Web of Science ®Google Scholar
• Moller AH, Erntoft S, Vinding GR, et al. A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D-derived utility values. Patient Relat Outcome Meas. 2015;6:167–177.
   PubMedGoogle Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65(1):137–174.
   PubMed Web of Science ®Google Scholar
• Levy AR, Davie AM, Brazier NC, et al. Economic burden of moderate to severe plaque psoriasis in Canada. Int J Dermatol. 2012;51(12):1432–1440.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Malakouti M, Koo JY. Social impact of the burden of psoriasis: effects on patients and practice. Dermatol Online J. 2014;20(8).
   Google Scholar
• Thomsen SF, Skov L, Dodge R, et al. Socioeconomic costs and health inequalities from psoriasis: a cohort study. Dermatology. 2019;25:1–8.
   Google Scholar
• Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1–10.
   PubMed Web of Science ®Google Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643–659.
   PubMed Web of Science ®Google Scholar
• Mason A, Mason J, Cork M, et al. Topical treatments for chronic plaque psoriasis: an abridged Cochrane systematic review. J Am Acad Dermatol. 2013;69(5):799–807.
   PubMed Web of Science ®Google Scholar
• Davis SA, Feldman SR. Combination therapy for psoriasis in the United States. J Drugs Dermatol. 2013;12(5):546–550.
   PubMed Web of Science ®Google Scholar
• Iversen L, Lange MM, Bissonette R, et al. Topical treatment of psoriasis: questionnaire results on topical therapy accessibility and influence of body surface area on usage. J Eur Acad Dermatol Venereol. 2017;31(7):1188–1195.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Tyring S, Bukhalo M, et al. Fixed combination aerosol foam calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD) is more efficacious than Cal or BD aerosol foam alone for psoriasis vulgaris: a randomized, double-blind, multicenter, three-arm, Phase 2 study. J Clin Aesthet Dermatol. 2016;9(2):34–41.
   PubMedGoogle Scholar
• Stein Gold L, Lebwohl M, Menter A, et al. Aerosol foam formulation of fixed combination calcipotriene plus betamethasone dipropionate is highly efficacious in patients with psoriasis vulgaris: pooled data from three randomized controlled studies. J Drugs Dermatol. 2016;15(8):951–957.
   PubMed Web of Science ®Google Scholar
• Menter A, Gold LS, Koo J, et al. Fixed-combination calcipotriene plus betamethasone dipropionate aerosol foam is well tolerated in patients with psoriasis vulgaris: pooled data from three randomized controlled studies. Skinmed. 2017;15(2):119–124.
   PubMedGoogle Scholar
• Paul C, Stein Gold L, Cambazard F, et al. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. J Eur Acad Dermatol Venereol. 2017;31(1):119–126.
   PubMed Web of Science ®Google Scholar
• Koo J, Tyring S, Werschler WP, et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris – A randomized phase II study. J Dermatolog Treat. 2016;27(2):120–127.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Bagel J, Yamauchi P, et al. Efficacy and safety of calcipotriene plus betamethasone dipropionate aerosol foam in patients with Psoriasis vulgaris a randomized phase III study (PSO-FAST)). J Drugs Dermatol. 2015;14(12):1468–1477.
   PubMed Web of Science ®Google Scholar
• Enstilar®. Calcipotriene and betamethasone dipropionate [package insert]. Madison, NJ: LEO Pharma Inc; 2019.
   Google Scholar
• Lebwohl M, Lombardi K, Tan MH. Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of maintenance treatments. Int J Dermatol. 2001;40(1):64–66.
   PubMed Web of Science ®Google Scholar
• Koo JY, Martin D. Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis. Int J Dermatol. 2001;40(3):210–212.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Breneman DL, Goffe BS, et al. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol. 1998;39(4):590–596.
   PubMed Web of Science ®Google Scholar
• DuobriiTM. Halobetasol propionate and tazaroten [package insert]. Quebec (Canada): Bausch Health Companies, Inc.; 2019.
   Google Scholar
• Stein Gold L, Lebwohl MG, Sugarman JL, et al. Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: results of 2 phase 3 randomized controlled trials. J Am Acad Dermatol. 2018;79(2):287–293.
   PubMed Web of Science ®Google Scholar
• Sugarman JL, Weiss J, Tanghetti EA, et al. Safety and efficacy of a fixed combination halobetasol and tazarotene lotion in the treatment of moderate-to-severe plaque psoriasis: a pooled analysis of two Phase 3 studies. J Drugs Dermatol. 2018;17(8):855–861.
   PubMed Web of Science ®Google Scholar
• Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics. 2010;28(10):935–945.
   PubMed Web of Science ®Google Scholar
• Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940–947.
   PubMed Web of Science ®Google Scholar
• Strand V, McInnes I, Mease P, et al. Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis. J Comp Eff Res. 2019;8(7):497–510.
   PubMed Web of Science ®Google Scholar
• Strand V, Betts KA, Mittal M, et al. Comparative effectiveness of adalimumab versus secukinumab for the treatment of psoriatic arthritis: a matching-adjusted indirect comparison. Rheumatol Ther. 2017;4(2):349–362.
   PubMed Web of Science ®Google Scholar
• Bewley AP, Shear NH, Calzavara-Pinton PG, et al. Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison. J Eur Acad Dermatol Venereol. 2019;33(6):1107–1115.
   PubMed Web of Science ®Google Scholar
• Chan A, Cutter G, Fox RJ, et al. Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: results of a matching-adjusted indirect comparison. J Comp Eff Res. 2017;6(4):313–323.
   PubMed Web of Science ®Google Scholar
• Atkins MB, Tarhini A, Rael M, et al. Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison. Immunotherapy. 2019;11(7):617–629.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Muresan B, Mamolo C, et al. Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia. Curr Med Res Opin. 2019;35(9):1615–1622.
   PubMed Web of Science ®Google Scholar
• Warren RB, Brnabic A, Saure D, et al. Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab. Br J Dermatol. 2018;178(5):1064–1071.
   PubMed Web of Science ®Google Scholar
• Langley RG, Feldman SR, Nyirady J, et al. The 5-point Investigator’s Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2015;26(1):23–31.
   PubMed Web of Science ®Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683–691.
   PubMed Web of Science ®Google Scholar
• Phillippo DM, Ades AE, Dias S, et al. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38(2):200–211.
   PubMed Web of Science ®Google Scholar
• Nyeland ME, Becla L, Patel DS, et al. Calcipotriene plus betamethasone dipropionate (0.005%/0.064%) foam and apremilast: matching-adjusted indirect comparison and US cost per responder analyses. Poster session presented at the Fall Clinical Dermatology Conference; 2018 Oct 18–21; Las Vegas, NV.
   Google Scholar
• Foley P, Garrett S, Ryttig L. A cost-effectiveness analysis of calcipotriol plus betamethasone dipropionate aerosol foam versus gel for the topical treatment of plaque psoriasis. Curr Med Res Opin. 2018;34(7):1277–1283.
   PubMed Web of Science ®Google Scholar
• Duvetorp A, Levin L, Engerstedt Mattsson E, et al. A cost-utility analysis of calcipotriol/betamethasone dipropionate aerosol foam versus ointment for the topical treatment of psoriasis vulgaris in Sweden. Acta Derm Venereol. 2019;99(4):393–399.
   PubMed Web of Science ®Google Scholar
• Affleck AG, Bottomley JM, Auland M, et al. Cost effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of scalp psoriasis in Scotland. Curr Med Res Opin. 2011;27(1):269–284.
   PubMed Web of Science ®Google Scholar
• Sawyer L, Samarasekera EJ, Wonderling D, et al. Topical therapies for the treatment of localized plaque psoriasis in primary care: a cost-effectiveness analysis. Br J Dermatol. 2013;168(5):1095–1105.
   PubMed Web of Science ®Google Scholar